Brokerage Firm Rating Update on Mead Johnson Nutrition Company (MJN)

Mead Johnson Nutrition Company (MJN) : 3 brokerage houses believe that Mead Johnson Nutrition Company (MJN) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. 7 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Mead Johnson Nutrition Company (MJN). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 11 Wall Street Analysts endorse the stock as a Buy with a rating of 2.36.

Mead Johnson Nutrition Company (MJN) has been rated by 6 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $96 and the lowest price target forecast is $75. The average forecast of all the analysts is $87.67 and the expected standard deviation is $6.98.


For the current week, the company shares have a recommendation consensus of Buy. Also, UBS initiates coverage on Mead Johnson Nutrition Company (NYSE:MJN) . Analysts at the UBS have a current rating of Neutral on the shares. The rating by the firm was issued on August 24, 2016.

Mead Johnson Nutrition Company (NYSE:MJN): stock was range-bound between the intraday low of $79.61 and the intraday high of $84.28 after having opened at $84.28 on Wednesdays session. The stock finally closed in the red at $84.28, a loss of -5.53%. The stock remained in the red for the whole trading day. The total traded volume was 4,032,064 shares. The stock failed to cross $84.28 in Wednesdays trading. The stocks closing price on Thursday was $84.64.

Mead Johnson Nutrition Company (Mead Johnson) is a global pediatric nutrition company. The Company manufactures, distributes and sells infant formulas, childrens nutrition and other nutritional products. Its product portfolio includes routine and specialty infant formulas, childrens milks and milk modifiers, dietary supplements for pregnant and breastfeeding mothers, pediatric vitamins, and products for pediatric metabolic disorders. The Company operates through three segments: Asia, Latin America and North America/Europe. The Companys Enfa family of brands, including Enfamil infant formula, is a brand franchise in pediatric nutrition. Its product portfolio addresses a range of nutritional needs for infants, children and expectant and nursing mothers. The Company markets its portfolio of more than 70 products to mothers, healthcare professionals and retailers in more than 50 countries in Asia, North America, Latin America and Europe.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.